Biosimilar uptake in public hospitals: NHS Hospitals

By HEOR Staff Writer

January 25, 2023

The Role of Time in Biosimilar Uptake

Biosimilars are gaining traction in the healthcare industry, with their use reaching 50% or more in public hospitals within three years of their first introduction. However, the uptake of these medical products varies greatly, with some hospitals fully embracing biosimilars, while others show little to no use. This article explores the uptake of biosimilars in public hospitals, providing an in-depth analysis based on recent research.

In the last decade, health systems have been challenged by the market entry of new drugs with high prices. In 2021 biologic drugs accounted for 78.6 billion euros in spending, and 34% of drug expenditures in Europe. Among these, 80% of the main nine therapy classes were exposed to biosimilar competition. This longitudinal analysis of Portuguese NHS hospitals shows that if all NHS hospitals had biosimilar shares equal to the highest ones, potential annual savings could reach 13.9 million euros.

Factors Influencing Biosimilar Adoption

Several factors influence the adoption of biosimilars in public hospitals. These include the type of drug, the hospital’s relationship with pharmaceutical companies, and the hospital’s financial situation. Interestingly, hospitals with higher debts were not more likely to adopt biosimilars, contrary to expectations. Time plays a crucial role in the adoption of biosimilars. As physicians and patients gain experience with these treatments, their use tends to increase. This trend suggests that education and communication efforts could significantly influence biosimilar uptake.

Despite the potential savings that biosimilars offer, their adoption in academic and large hospitals is slower than expected. This finding suggests a need for stronger management, communication, and educational efforts to promote biosimilar uptake in public hospitals. 

Reference url

Recent Posts

Oral Semaglutide Benefits: EMA Approves First Oral GLP-1 RA with Cardiovascular Perks

By HEOR Staff Writer

September 16, 2025

Novo Nordisk’s oral semaglutide (Rybelsus®) has received a significant label update from the European Medicines Agency (EMA). It is now the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved in the EU for type 2 diabetes with proven cardiovascular benefits. This deci...
Ending Unproven Fertility Treatments: NICE Calls for Evidence-Based Care in Clinics

By João L. Carapinha

September 10, 2025

Unproven fertility treatments—a term referring to add-on procedures without robust clinical evidence—have come under renewed scrutiny in the UK. Many prospective parents want to know: Why are unproven fertility treatments being discouraged, and what does this mean for fertility clinic choices...
UK Risks Underestimating Life Sciences Investment Potential

By HEOR Staff Writer

September 8, 2025

Life sciences investment UK is at a crucial crossroads. As the government relies on the Green Book framework to guide funding for manufacturing innovation, many experts question whether the true value of advanced life sciences manufacturing is being fully recognized. How does the current appraisa...